drugset / Trial / NCT02909452
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK), impact on immune correlatives, and efficacy
Timeline
- Start
- 2016-09-20
- Primary completion
- 2019-07-17
- Completion
- 2021-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Entinostat | Small molecule | 1 mg | — |
| Comparator | Entinostat | Small molecule | 5 mg | — |
| Comparator | Entinostat | Small molecule | 10 mg | — |
| Comparator | Pembrolizumab | Monoclonal antibody | — | — |